Studying immune cells around pituitary tumors to find useful markers
Examines immune features in pituitary tumors of adults, looking for markers and treatment targets.
Key facts
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- NET-TIME: Inflammatory Tumor Microenvironment in Pituitary Neoplasm
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 3 Jun 2023
- Expected to end
- 31 Mar 2027
- Type of study
- Observational
- Record updated
- 18 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a pituitary tumor (PitNET) who are due to have surgery to remove it. The study looks at immune cells and markers inside the tumor.
- Age
- Over 18 years of age (record lists 18 Years to 100 Years).
- Sex
- All sexes can join.
- Disease stage
- A pituitary tumor (PitNET) that needs surgical removal under current guidelines. The diagnosis must be confirmed by tissue study after surgery.
- Earlier treatment
- No medical (drug) therapy for the tumor before surgery. This includes no somatostatin analogs or dopamine agonists.
Main reasons for not taking part
- Past treatment with somatostatin analogs or dopamine agonists before tumor removal
- Radiotherapy to the head and neck region earlier than 10 years after removal of the pituitary adenoma
- History of autoimmune diseases
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- indication as per clinical practice and in agreement to current guidelines for surgical removal of the PitNET0
- patient naïve to medical therapy before surgical removal of PitNET
- Diagnosis of PitNET confirmed through the study pathological/histological
- over 18 years of age
- acceptance of participation in the study, by signing an informed consent
Who cannot take part
- History of medical therapy with analogs of somatostatin or dopamine agonist, previous the removal of the pituitary adenoma
- history of radiotherapy of the head and neck region earlier than 10 years after resection of the adenoma pituitary
- history of autoimmune diseases
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Over the past twenty years, a progressively increasing number of markers biochemical, clinical, imaging, histopathological or genetic have been suggested to attempt to predict aggression and therapeutic outcome, both in secretory PitNETs and in non-secretory PitNETs. In recent years, the microenvironment tumor (TEM) has been extensively studied in different malignancies, promoting the development of therapies target and immunotherapy with checkpoint inhibitors immune system (ICI). Data on TIME in PitNETs are scarce today and derive from studies conducted mainly on heterogeneous cases for type of PitNET. Therefore, the purpose of this research project is to investigate the TIME in PitNET, to identify immune biomarkers and new molecular pathways that can promote the use of ICI and target therapies in Aggressive PitNETs.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Inflammatory Tumor Microenvironment in Pituitary Neoplasm
- Plain-language title
- Studying immune cells around pituitary tumors to find useful markersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07594262, who can take part
- Record updated
- 18 May 2026